FTSE 10010,410.00 +0.60% Nikkei 22554,313.90 -0.41% Stock Market Live March 17, 2026: S&P 500 (SPY) Flat as Oil Gushes Higher From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here - 24/7 Wall St. S&P 5006,726.10 +0.28% Dow Jones47,021.00 +0.18% Nasdaq 10024,789.20 +0.43% Russell 20002,513.87 +0.38% Investing From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here By Joel SouthPublished Mar 17, 12:16PM EDT Quick Read CRISPR Therapeutics (CRSP) holds $2.56B in p ...

Group 1 - Crispr Therapeutics Ag (NASDAQ:CRSP) has seen a 16% increase in share price over the past 12 months, with ARK Investment increasing its stake by 8% in Q4, resulting in a $10.5 million position [1] - The company holds a first-mover advantage in the gene editing and gene therapy sectors, with its CRISPR-based treatment already approved by the FDA [2] - Crispr's CASGEVY therapy for severe sickle cell disease and beta-thalassemia is generating revenue through a partnership with Vertex Pharmaceuticals [2] Group 2 - Hedge fund sentiment towards Crispr Therapeutics increased in Q4, with 32 funds holding the stock, up from 31 in the previous quarter [3] - The FDA approved Crispr's CRISPR-Cas9 gene editing therapy for sickle cell disease in December 2023, after nearly six years of clinical trials [3] - The therapy, Casgevy, disrupts the BCL11A gene to promote the production of fetal hemoglobin, providing a functional cure for sickle cell disease, which affects approximately 1 in 365 Black or African American births [3] - The treatment costs about $2.2 million per use but is expected to be a one-time treatment, with potential lifetime healthcare savings estimated between $4 million and $6 million [3] - Crispr retains 40% of profits from the partnership with Vertex, which has invested nearly $1.1 billion to increase its stake in the commercialization of Casgevy [3]

Financial Performance - CRISPR Therapeutics reported total revenue of $116 million for FY2025, with $54 million generated in Q4 alone, driven by a nearly threefold increase in patient initiations compared to the previous year [1][6] - A total of 147 patients have started treatment for sickle cell disease or beta thalassemia, supported by expanded reimbursement access across the US, Europe, and the Middle East [1] Product Development - The company is advancing a diverse 'in vivo' liver editing portfolio using lipid nanoparticles, with key programs including CTX310 for cardiovascular conditions and CTX460 for alpha-1 antitrypsin deficiency, expected to enter clinical trials in mid-2026 [2] - CRISPR is collaborating with Sirius Therapeutics on siRNA-based programs targeting thromboembolic diseases, with Phase 2 data for their lead Factor XI candidate expected in H2 2026 [3] - The clinical pipeline includes 'zugo-cel,' a CAR-T cell therapy for autoimmune diseases and B-cell cancers, and CTX213, an islet cell replacement candidate for Type 1 diabetes showing promising preclinical efficacy [3] Technology and Innovation - CRISPR Therapeutics utilizes its Cas9 platform to develop gene-based medicines for serious human diseases [4]

Vertex Pharmaceuticals FY Conference Summary Company Overview - **Company**: Vertex Pharmaceuticals (NasdaqGS: VRTX) - **Industry**: Biotechnology, focusing on cystic fibrosis and expanding into renal and pain management therapies Key Points Strategic Diversification - Vertex has transitioned from a cystic fibrosis-focused company to a more diversified biotech firm, aiming to broaden its revenue base and patient demographics [2][3] - The company has launched ALYFTREK, its fifth commercialized medicine, and is developing a next-gen 3.0 family of therapies [2] Revenue Projections - Vertex expects combined revenue from CASGEVY (for sickle cell disease and beta thalassemia) and Journavx (for acute pain) to exceed $500 million in 2026 [3] - Journavx is projected to triple the number of prescriptions in 2026 compared to 2025, with revenue growth expected to outpace prescription growth [3] Renal Franchise Development - Vertex aims to establish a renal franchise comparable in size to its cystic fibrosis business, with three ongoing phase 3 programs and a phase 2 study for autosomal dominant polycystic kidney disease [4] - The company is committed to R&D in serious diseases with validated markers and efficient clinical pathways [5] Povetacicept Data Highlights - Povetacicept shows a 52% reduction in UPCR at 36 weeks, with significant secondary endpoint results: 77% reduction in Gd-IgA1 and 85% resolution of hematuria [7][8] - 42% of patients achieved KDIGO recommended guidelines of UPCR less than 0.5 grams per gram, indicating strong efficacy in a real-world patient population [9] Safety Profile - The safety profile of povetacicept is favorable, with most adverse events being mild or moderate and no serious adverse events related to the drug [19] - No discontinuations due to infections were reported, and common adverse events included upper respiratory tract infections and injection site reactions [19] Future Studies and Indications - Vertex is conducting phase 2/3 studies for primary membranous nephropathy and plans to initiate a phase 2 study for myasthenia gravis in the first half of the year [23][24] - The company sees potential for povetacicept in multiple conditions, with ongoing discussions about commercial opportunities in nephrology [26] Cystic Fibrosis Business Update - ALYFTREK is expected to see continued growth, with a focus on younger patients and rare mutations, particularly in Europe [35] - The company reported that 30% of patients aged 12+ and over 60% of patients aged 2-5 are achieving diagnostic levels, indicating strong treatment efficacy [37] Journavx Commercial Strategy - Vertex is doubling its sales force from 150 to 300 reps to enhance physician access and drive adoption of Journavx [44] - The company is increasing marketing investments, including direct-to-consumer advertising, to boost awareness and uptake [44] Upcoming Trials - Vertex is conducting two phase 3 trials for diabetic peripheral neuropathy, with enrollment expected to complete by year-end, setting the stage for results in 2027 [50] Conclusion - Vertex Pharmaceuticals is strategically diversifying its portfolio beyond cystic fibrosis, with promising developments in renal therapies and pain management. The company is focused on maintaining a strong safety profile while driving revenue growth through innovative therapies and expanding its commercial capabilities.

Vertex Pharmaceuticals Conference Call Summary Company Overview - **Company**: Vertex Pharmaceuticals (NasdaqGS: VRTX) - **Date**: March 10, 2026 - **Key Focus**: Discussion on company goals, product pipeline, and financial outlook Core Industry Insights 1. Company Goals for 2026 - Extend leadership in Cystic Fibrosis (CF) - Accelerate commercial diversification, particularly with DRNAvx and CASGEVY - Advance a broad pipeline with five ongoing Phase 3 trials - Deliver consistent financial results with revenue guidance of **$12.95 billion to $13.1 billion**, indicating **8%-9% growth** [7][8] 2. Product Pipeline and Efficacy Data - **POVI (povotazacet)**: - Recent data showed a **52% reduction in UPCR** at 36 weeks compared to baseline and a **50% reduction relative to placebo** [9] - Secondary endpoints showed a **77% reduction in Gd-IgA1 antibodies** and an **85% resolution rate in hematuria** [9] - Safety profile was strong with no serious adverse events (SAEs) related to POVI and no deaths in the trial [10] - Filing for regulatory approval expected by the end of March 2026 [11] 3. Commercialization Strategy - POVI is positioned as a potential best-in-class product due to its efficacy, safety, and convenient dosing [30] - The company is gearing up for a launch, having started planning in mid-2025 [31] 4. Growth Prospects - Continued growth in CF expected, with ongoing launches of ALYFTREK in the U.S. and internationally [22] - Anticipated tripling of JOURNAVX prescriptions in 2026, with coverage for approximately **200 million lives** [23][58] - Non-CF products like CASGEVY and JOURNAVX expected to become multibillion-dollar businesses [24][25] 5. Financial Outlook - Operating margins maintained in the low-to-mid **40% range** despite ongoing investments in the pipeline [24] - Investments in five Phase 3 trials and commercial organization for new products are expected to drive growth [24] Additional Important Insights 1. Competitive Landscape - Comparison with competitors like ATSUCA, noting that their data is at a later time point (week 40) [13] - Emphasis on the real-world population in the study, with a significant time from diagnosis to enrollment [19] 2. Future Data Releases - Additional data from ongoing trials will be released at appropriate times, with a focus on maintaining transparency with stakeholders [12] 3. Patient Support Programs - Medicare patients currently have access to JOURNAVX through a patient support program until formal coverage is secured [61][64] 4. Upcoming Milestones - Phase 3 results for DPN expected in late 2026 or early 2027 [26] - VX-828 Phase 1b data anticipated in the second half of 2026 [70][74] 5. CASGEVY Progress - Positive progress noted with over **300 patients** starting treatment in 2025, with expectations for continued growth in 2026 [76] This summary encapsulates the key points discussed during the Vertex Pharmaceuticals conference call, highlighting the company's strategic goals, product pipeline advancements, and financial outlook.

Core Insights - CRISPR Therapeutics AG (NASDAQ:CRSP) is recognized as one of the 10 most shorted biotech stocks to consider for investment by hedge funds [1] - Morgan Stanley raised its price target for CRISPR Therapeutics from $32 to $33 while maintaining an Underweight rating [1] - Needham increased its price target from $80 to $82, maintaining a Buy rating, indicating over 45% upside potential [2] Financial Performance - Casgevy, a therapy developed by CRISPR's partner Vertex Pharmaceuticals, generated $116 million in sales in 2025, exceeding the previous target of approximately $100 million [2] - The strong sales performance of Casgevy indicates early commercial traction and supports a positive outlook for CRISPR Therapeutics [2] Company Overview - CRISPR Therapeutics is a gene editing company focused on developing potentially curative medicines for serious diseases, including sickle cell disease and blood disorders [3] - The company's broader pipeline also addresses cancer, autoimmune conditions, and diabetes, positioning it as a leader in the future of genetic medicine [3]

Industry Overview - J.P. Morgan highlights trends defining healthcare in 2026, particularly in the biopharma segment, which is gaining momentum and attracting investor interest [1] - Mergers and acquisitions in the biopharma sector are increasing as companies seek to bolster their pipelines ahead of patent expirations for major drugs [1] - Investors are optimistic about smaller biopharma companies with promising drugs and clear value paths, alongside a convergence of biotech and digital health [2] Investment Opportunities - There is an expectation of more deals in 2026 and key clinical results on the horizon, presenting opportunities for informed investors [2] - A methodology was employed to identify U.S.-listed biotechnology companies with market capitalizations above $2 billion, a short interest ratio greater than 15%, and at least 15% upside potential [5][6] Hedge Fund Interest - The focus on stocks that hedge funds are investing in is based on research indicating that mimicking top hedge fund picks can lead to market outperformance [7] - The article lists the 10 most shorted biotech stocks to buy according to hedge funds, indicating strong interest and potential for growth [3] Company Spotlight: CRISPR Therapeutics AG - CRISPR Therapeutics AG is identified as one of the most shorted biotech stocks to buy, with significant attention from hedge funds [8] - Morgan Stanley raised its price target for CRISPR Therapeutics AG from $32 to $33 while maintaining an Underweight rating, reflecting updated estimates and pipeline evaluations [9] - Needham increased its price target for CRISPR Therapeutics AG from $80 to $82, maintaining a Buy rating with over 45% upside potential [10] - The company reported that its therapy Casgevy generated $116 million in sales in 2025, exceeding expectations and indicating strong commercial traction [11] - CRISPR Therapeutics AG focuses on gene editing to develop potentially curative medicines for serious diseases, positioning itself as a leader in genetic medicine [12]

Group 1 - CRISPR Therapeutics AG (NASDAQ:CRSP) is included in the ARK Invest Stock Portfolio as one of the top 10 stock picks for 2026, with a stake value exceeding $551 million as of Q4 2025 [1] - The company currently holds a Moderate Buy rating from analysts, with an average share price upside of 17% as of March 4 [1] - Truist Financial analyst Joon Lee reaffirmed a Buy rating for CRISPR Therapeutics on March 2, indicating continued analyst interest [1] Group 2 - Chardan Capital raised its price target for CRISPR Therapeutics AG to $76 from $74 while maintaining a Buy rating, following the company's business update and Q4 results announcement on February 12 [2] - Analyst Geulah Livshits from Chardan noted the positive momentum in the company's siRNA therapies and vivo cardiovascular editing, along with advancements in various clinical and preclinical programs [3] - Following the Q4 report, TD Cowen increased its price target to $45 from $40, maintaining a Hold rating, and highlighted strong momentum in CASGEVY, which generated quarterly revenue of $54 million and full-year revenue of $116 million [4] Group 3 - CRISPR Therapeutics AG focuses on developing CRISPR/Cas9-based therapeutics aimed at treating genetically-defined diseases and engineering advanced cellular therapies [5]

On the operational side, management emphasized the internalization of the manager as a “large and complex step,” intended to better align governance and incentives with unitholders and improve economic returns. Hedayat said early results have shown “significant gains,” and that the company feels better about the “pace and magnitude of benefits” than when the internalization was first announced. He also noted cost structure optimization contributed to the trust’s highest-ever normalized margins, and the comp ...

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $3.2 billion, a 10% increase compared to Q4 2024. For the full year 2025, total revenue was $12 billion, reflecting a 9% increase versus 2024 [32][33] - Non-GAAP net income for Q4 2025 was $1.3 billion, up 24% year-over-year, resulting in earnings per share of $5.03, a 26% increase compared to the prior year [37] - The company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments [37] Business Line Data and Key Metrics Changes - Cystic fibrosis (CF) therapies generated a full year 2025 growth of 7% globally, with U.S. CF revenue growing 11% year-over-year [32][33] - CASGEVY achieved $54 million in revenue in Q4 and $116 million for the full year 2025, demonstrating continued momentum in patient initiations [34][35] - JOURNAVX delivered $27 million in sales in Q4 and $60 million for the full year, with substantial growth in quarterly prescriptions since its launch [34] Market Data and Key Metrics Changes - The CF population has seen a 3% annual increase over the last five years, contributing to revenue growth [22] - In Europe, reimbursement for ALYFTREK has been secured in key countries, including the UK, Germany, and Italy, expanding access to CFTR modulators [22][23] - CASGEVY's reimbursement agreements in the U.S. have reached approximately 90% access for both Medicaid and commercial patients [23] Company Strategy and Development Direction - The company aims to expand leadership in CF, accelerate adoption of CASGEVY, and grow JOURNAVX while advancing its renal franchise [6][29] - The renal pipeline is emerging as a key growth engine, with povetacicept positioned to address significant unmet needs in IgA nephropathy and membranous nephropathy [10][29] - The company is focused on commercial execution and innovation to drive sustained growth across multiple serious disease areas [6][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on significant opportunities and drive sustained growth through commercial execution and innovation [6][40] - The guidance for 2026 anticipates total company revenue in the range of $12.95 billion to $13.1 billion, representing 8%-9% growth versus the prior year [38] - The company expects combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as it continues to invest in its late-stage clinical pipeline [39] Other Important Information - The company has initiated a rolling BLA submission for povetacicept, with expectations for expedited regulatory review [11] - The company is committed to maintaining comprehensive patient support programs to facilitate access to its therapies [29] Q&A Session Summary Question: Concerns about hypogammaglobulinemia adverse events related to povetacicept - Management indicated that while BAFF/APRIL inhibitors may decrease IgG levels, data from the RUBY-3 study showed no serious adverse events or infections associated with low IgG levels, suggesting a favorable benefit-risk profile [42][44] Question: Guidance details for CF component and ALYFTREK - Management provided total revenue guidance of $12.95 billion to $13.1 billion, with a non-CF contribution of $500 million or more, but did not break down specifics for ALYFTREK versus other products [49][51] Question: Payer access and reimbursement for povetacicept - Management reported positive engagements with payers, having conducted 74 meetings covering over 210 million lives, indicating strong interest in the upcoming products [55][60] Question: Expected results on proteinuria for povetacicept - Management emphasized the importance of magnitude of proteinuria response, referencing a 56% reduction seen in the RUBY-3 study as a benchmark for expected outcomes [62][64] Question: Differentiation of povetacicept in generalized myasthenia gravis - Management highlighted the engineered profile of povetacicept, which offers better potency and pharmacokinetics compared to existing treatments, positioning it as a promising option in a crowded market [68][70]